From the conclusion:
“These data suggest that the vast majority of patients who develop MIS-C present with GI symptoms mimicking GI infection or even inflammatory bowel disease, MIS-C should thus be considered in patients with prominent GI symptoms and a history of recent SARS-CoV-2 exposure or infection. Although not uniformly, MIS-C can differ from these other conditions in both its clinical comorbidities as well as extremely high inflammatory markers. Amongst follow-up for other potential sequelae of organ dysfunction, long-term follow-up for the GI manifestations in some of these patients may warrant surveillance for IBD.”